Literature DB >> 28739781

Structural Insights into the TLA-3 Extended-Spectrum β-Lactamase and Its Inhibition by Avibactam and OP0595.

Wanchun Jin1, Jun-Ichi Wachino2, Yoshihiro Yamaguchi3, Kouji Kimura1, Anupriya Kumar1, Mototsugu Yamada4, Akihiro Morinaka4, Yoshiaki Sakamaki4, Minoru Yonezawa4, Hiromasa Kurosaki5, Yoshichika Arakawa1.   

Abstract

The development of effective inhibitors that block extended-spectrum β-lactamases (ESBLs) and restore the action of β-lactams represents an effective strategy against ESBL-producing Enterobacteriaceae We evaluated the inhibitory effects of the diazabicyclooctanes avibactam and OP0595 against TLA-3, an ESBL that we identified previously. Avibactam and OP0595 inhibited TLA-3 with apparent inhibitor constants (Kiapp) of 1.71 ± 0.10 and 1.49 ± 0.05 μM, respectively, and could restore susceptibility to cephalosporins in the TLA-3-producing Escherichia coli strain. The value of the second-order acylation rate constant (k2/K, where k2 is the acylation rate constant and K is the equilibrium constant) of avibactam [(3.25 ± 0.03) × 103 M-1 · s-1] was closer to that of class C and D β-lactamases (k2/K, <104 M-1 · s-1) than that of class A β-lactamases (k2/K, >104 M-1 · s-1). In addition, we determined the structure of TLA-3 and that of TLA-3 complexed with avibactam or OP0595 at resolutions of 1.6, 1.6, and 2.0 Å, respectively. TLA-3 contains an inverted Ω loop and an extended loop between the β5 and β6 strands (insertion after Ser237), which appear only in PER-type class A β-lactamases. These structures might favor the accommodation of cephalosporins harboring bulky R1 side chains. TLA-3 presented a high catalytic efficiency (kcat/Km ) against cephalosporins, including cephalothin, cefuroxime, and cefotaxime. Avibactam and OP0595 bound covalently to TLA-3 via the Ser70 residue and made contacts with residues Ser130, Thr235, and Ser237, which are conserved in ESBLs. Additionally, the sulfate group of the inhibitors formed polar contacts with amino acid residues in a positively charged pocket of TLA-3. Our findings provide a structural template for designing improved diazabicyclooctane-based inhibitors that are effective against ESBL-producing Enterobacteriaceae.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  ESBL; OP0595; TLA-3; avibactam; crystal structure; diazabicyclooctane; extended-spectrum β-lactamase

Mesh:

Substances:

Year:  2017        PMID: 28739781      PMCID: PMC5610492          DOI: 10.1128/AAC.00501-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  35 in total

Review 1.  Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections.

Authors:  Marco Falcone; David Paterson
Journal:  J Antimicrob Chemother       Date:  2016-07-17       Impact factor: 5.790

2.  Extended-spectrum β-lactamase (ESBL)-producing Escherichia coli isolates collected from diseased food-producing animals in the GERM-Vet monitoring program 2008-2014.

Authors:  Geovana Brenner Michael; Heike Kaspar; Amanda Keller Siqueira; Eduardo de Freitas Costa; Luís Gustavo Corbellini; Kristina Kadlec; Stefan Schwarz
Journal:  Vet Microbiol       Date:  2016-09-01       Impact factor: 3.293

3.  Avibactam and inhibitor-resistant SHV β-lactamases.

Authors:  Marisa L Winkler; Krisztina M Papp-Wallace; Magdalena A Taracila; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2015-02-17       Impact factor: 5.191

4.  Exploring the Landscape of Diazabicyclooctane (DBO) Inhibition: Avibactam Inactivation of PER-2 β-Lactamase.

Authors:  Melina Ruggiero; Krisztina M Papp-Wallace; Magdalena A Taracila; Maria F Mojica; Christopher R Bethel; Susan D Rudin; Elise T Zeiser; Gabriel Gutkind; Robert A Bonomo; Pablo Power
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

5.  OP0595, a new diazabicyclooctane: mode of action as a serine β-lactamase inhibitor, antibiotic and β-lactam 'enhancer'.

Authors:  Akihiro Morinaka; Yuko Tsutsumi; Mototsugu Yamada; Kenji Suzuki; Takashi Watanabe; Takao Abe; Takeshi Furuuchi; Seiichi Inamura; Yoshiaki Sakamaki; Nakako Mitsuhashi; Takashi Ida; David M Livermore
Journal:  J Antimicrob Chemother       Date:  2015-06-18       Impact factor: 5.790

6.  Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor.

Authors:  David E Ehmann; Haris Jahić; Philip L Ross; Rong-Fang Gu; Jun Hu; Gunther Kern; Grant K Walkup; Stewart L Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-02       Impact factor: 11.205

7.  iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM.

Authors:  T Geoff G Battye; Luke Kontogiannis; Owen Johnson; Harold R Powell; Andrew G W Leslie
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2011-03-18

8.  Crystal structure of the extended-spectrum β-lactamase PER-2 and insights into the role of specific residues in the interaction with β-lactams and β-lactamase inhibitors.

Authors:  Melina Ruggiero; Frédéric Kerff; Raphaël Herman; Frédéric Sapunaric; Moreno Galleni; Gabriel Gutkind; Paulette Charlier; Eric Sauvage; Pablo Power
Journal:  Antimicrob Agents Chemother       Date:  2014-07-28       Impact factor: 5.191

9.  CTX-M Enzymes: Origin and Diffusion.

Authors:  Rafael Cantón; José María González-Alba; Juan Carlos Galán
Journal:  Front Microbiol       Date:  2012-04-02       Impact factor: 5.640

10.  Protein crystallography beamline BL2S1 at the Aichi synchrotron.

Authors:  Nobuhisa Watanabe; Takayuki Nagae; Yusuke Yamada; Ayana Tomita; Naohiro Matsugaki; Masao Tabuchi
Journal:  J Synchrotron Radiat       Date:  2017-01-01       Impact factor: 2.616

View more
  7 in total

1.  Nacubactam Enhances Meropenem Activity against Carbapenem-Resistant Klebsiella pneumoniae Producing KPC.

Authors:  Melissa D Barnes; Magdalena A Taracila; Caryn E Good; Saralee Bajaksouzian; Laura J Rojas; David van Duin; Barry N Kreiswirth; Michael R Jacobs; Andreas Haldimann; Krisztina M Papp-Wallace; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

2.  Molecular Basis for the Potent Inhibition of the Emerging Carbapenemase VCC-1 by Avibactam.

Authors:  Chand S Mangat; Grishma Vadlamani; Viktor Holicek; Mitchell Chu; Veronica L C Larmour; David J Vocadlo; Michael R Mulvey; Brian L Mark
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

Review 3.  Exploring Additional Dimensions of Complexity in Inhibitor Design for Serine β-Lactamases: Mechanistic and Intra- and Inter-molecular Chemistry Approaches.

Authors:  Focco van den Akker; Robert A Bonomo
Journal:  Front Microbiol       Date:  2018-04-05       Impact factor: 5.640

4.  Dysgonomonas mossii Strain Shenzhen WH 0221, a New Member of the Genus Dysgonomonas Isolated from the Blood of a Patient with Diabetic Nephropathy, Exhibits Multiple Antibiotic Resistance.

Authors:  Xiaojuan Gao; Jiehong Wei; Tongyu Hao; Ting Yang; Xinyuan Han; Mengmeng Li; Xinying Li; Dan Xiong; Xiuming Zhang
Journal:  Microbiol Spectr       Date:  2022-08-01

5.  Molecular Basis of Class A β-Lactamase Inhibition by Relebactam.

Authors:  Catherine L Tooke; Philip Hinchliffe; Pauline A Lang; Adrian J Mulholland; Jürgen Brem; Christopher J Schofield; James Spencer
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.938

6.  Sulfamoyl Heteroarylcarboxylic Acids as Promising Metallo-β-Lactamase Inhibitors for Controlling Bacterial Carbapenem Resistance.

Authors:  Jun-Ichi Wachino; Wanchun Jin; Kouji Kimura; Hiromasa Kurosaki; Ayato Sato; Yoshichika Arakawa
Journal:  mBio       Date:  2020-03-17       Impact factor: 7.867

7.  Structural Investigations of the Inhibition of Escherichia coli AmpC β-Lactamase by Diazabicyclooctanes.

Authors:  Pauline A Lang; Thomas M Leissing; Malcolm G P Page; Christopher J Schofield; Jürgen Brem
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.938

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.